fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Busulfan

All products: general benefit

Myleran · DIN 00004618 · 2 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Myleran · DIN 00004618 Manufacturer: Aspen Pharma Trading Limited; listing date 1996-10-01 Health Canada: Marketed since 2018-07-24 · brand MYLERAN · ATC L01AB01 BUSULFAN · form Tablet · route Oral · ingredients BUSULFAN 2 MG · company Aspen pharmacare canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Myleran: Formulary list price $2.38 per unit (the source does not state the unit; exact figure $2.3788). What the ministry pays, not the patient.

Ministry pays: $2.3788 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00004618)

Source record
DIN 00004618: Myleran Raw flags: sec3=Y Item: 100000005; group id 148; item number 0251; lccId None; manufacturer id ASN Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $2.3788; ministry $2.3788 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00004618 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=959
Shortage status: resolved shortage (ended January 22, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00004618
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L01A): coverage varies; not interchangeable

  • Chlorambucil (Leukeran): general benefit
  • Cyclophosphamide (Procytox): general benefit, not a benefit
  • Lomustine ccnu (Gleostine): general benefit, listing status unconfirmed
  • Melphalan (Alkeran): general benefit
  • Temozolomide (Temodal): general benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

LOMUSTINE (CCNU)

· 5 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (1) · strengths: 10mg, 40mg, 100mg · Cap

MELPHALAN

· 1 products · General benefit · strengths: 2mg · Tab

TEMOZOLOMIDE

· 20 products · General benefit · strengths: 5mg, 20mg, 100mg, 140mg, 250mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MYLERAN® (busulfan) is indicated for: Chronic granulocytic (myelocytic, myeloid) leukemia for the production of remissions. May be used with extreme caution in patients with prior radiation or P 32 therapy and in those untreated by any other means. 1.1 Pediatrics Pediatrics (0-18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. In paediatric transplant recipients, dental development anomalies have been observed with busulfan-based conditioning regimens. (see WARNING AND PRECAUTIONS/Gastrointestinal AND ADVERSE REACTION sections). 1.2 Geriatrics Geriatrics (> 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00059855.PDF PM date: February 1, 2021 Source product: MYLERAN; DIN 00004618; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.